



COMPANY OVERVIEW

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

NeoGenomics Reports 17% Revenue Growth to Record \$69 Million

Oct 30 2018, 7:00 AM EDT

NeoGenomics Signs Definitive Agreement to Acquire Genoptix

Oct 23 2018, 7:00 AM EDT

NeoGenomics Schedules its Third Quarter Earnings Release for October 30, 2018

Oct 1 2018, 7:00 AM EDT

STOCK OVERVIEW

Symbol	NEO
Exchange	Nasdaq
Market Cap	1.5b
Last Price	\$16.11
52-Week Range	\$7.08 - \$19.040001

INVESTOR RELATIONS

William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

MANAGEMENT TEAM

Douglas M. VanOort

Chairman of the Board of Directors and Chief Executive Officer

Sharon Virag

Chief Financial Officer

Robert J. Shovlin

President, Clinical Services

George A. Cardoza

President, Pharma Services

Jennifer M. Balliet

Chief Culture Officer

William Bonello

Chief Strategy and Corporate Development Officer
Director, Investor Relations

Denise E. Pedulla

General Counsel

Steven A. Ross

Vice President, Chief Information Officer

Stephanie Bywater

Chief Compliance Officer

Steven G. Brodie, Ph.D.

Vice President of Worldwide Pharma Services Operations

Kathryn B. McKenzie

Vice President - Finance, Principal Accounting Officer

NEOGENOMICS, INC.

12701 Commonwealth Dr.
Suite 9
Fort Myers, FL 33913

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.